MaxCyte, Inc. Common Stock (MXCT) — Analysis Summary
MaxCyte, Inc. Common Stock (MXCT) has a market cap of $129.62M with year-over-year revenue growth of -5.7%. Net margin stands at -213.0%. The stock trades at a P/E ratio of -3.3.
Key Takeaways
- Revenue changed -5.7% year-over-year
- Net margin of -213.0%
- P/E ratio of -3.3
Compared to other companies in the SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH sector, MXCT posted revenue growth of -5.7% and trades at a P/E of -3.3.
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.